MT200605 / Shaanxi Micot Technology - LARVOL DELTA

Preclinical and first-in-human phase I trial of MT200605: A novel TrkB agonist for acute ischaemic stroke. (PubMed, Br J Clin Pharmacol) - "MT200605 shows promising preclinical neuroprotection and an acceptable safety profile with predictable PK in humans. A twice-daily intravenous regimen of 0.6 mg/kg (1.2 mg/kg/day) is recommended for phase II trials in acute ischaemic stroke patients."

Clinical • First-in-human • Journal • P1 data • Preclinical • Cardiovascular • Ischemic stroke • BDNF

A Clinical Trial of MT200605 for the Treatment of Acute Ischemic Stroke (clinicaltrials.gov) - P2 | N=360 | Recruiting | Sponsor: Shaanxi Micot Pharmaceutical Technology Co., Ltd.

New P2 trial • Cardiovascular • Ischemic stroke

A SAD/MAD Study to Evaluate the Safety, Tolerability, PK of MT200605 in Healthy Subjects (clinicaltrials.gov) - P1 | N=61 | Completed | Sponsor: Shaanxi Micot Technology Limited Company | Enrolling by invitation ➔ Completed | Trial completion date: Sep 2024 ➔ Feb 2024 | Trial primary completion date: Jul 2024 ➔ Jan 2024

Trial completion • Trial completion date • Trial primary completion date

A SAD/MAD Study to Evaluate the Safety, Tolerability, PK of MT200605 in Healthy Subjects (clinicaltrials.gov) - P1 | N=60 | Enrolling by invitation | Sponsor: Shaanxi Micot Technology Limited Company

New P1 trial